In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Minnesota Medical Development's Rebound HRD:

This article was originally published in Clinica

Executive Summary

The Rebound HRD hernia repair device developed by Minnesota Medical Development has been granted 510(k) clearance by the US FDA. The Rebound HRD is a self-expanding surgical mesh device composed of Nitinol, designed for the laparoscopic repair and/or reinforcement of both inguinal and ventral hernias. It conforms to the anatomy while providing stability, eliminating the need for anchoring, which, in turn, minimises patient post-op discomfort and the risk of nerve/blood vessel injury. It can also be used for other soft tissue defects where weakness exists and where the support of a non-absorbable material is preferred. The Plymouth, Minnesota company CE-marked the product for sale in the EU in June (see Clinica No 1261, p 22).

You may also be interested in...

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

FDA Wants To Put Hep C Tests On 510(k) Pathway

The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts